| gap-pubmed-20260410- | How does S404 phosphorylation mechanistically prime GSK3β for sequential phospho | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does complement-mediated synaptic pruning specifically affect glutamatergic | open | 0.77 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What is the causal relationship between gut microbiota changes and brain complem | resolved | 0.81 | 0.00 | 2026-04-10 | 0 | | gut-brain-axis |
| gap-pubmed-20260410- | How does XYS1 selectively target C1Q in microglia versus C3 in astrocytes across | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Why do RORB+ glutamatergic neurons specifically associate with cognitive status | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does TMEM106B influence cognitive resilience independently of AD pathology b | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms explain how PVALB+ neurons confer cognitive resilience despite A | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the major challenges in targeting R-loop helicases for therapeutic inte | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether helicases promote R-loop formation versus resolution in | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines tissue-specific sensitivity to butyrate-mediated mitophagy resto | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does butyrate selectively block RELA nuclear translocation without affecting | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie V1613M variant's modulation of APP processing | open | 0.84 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does the V1613M variant reduce amyloid pathology when ABCA7 loss-of-function | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the temporal relationship between neuroimmune activation and neu | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do mitochondrial dysfunction and cellular senescence mechanistically drive n | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the molecular mechanisms linking HIV-1 infection to accelerated brain a | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What is the relative contribution of cleaved vs intact GSDMD activation in neuro | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does ROS-dependent S-palmitoylation mechanistically activate intact GSDMD wi | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does FOXF2 mechanistically control chromatin accessibility at pro-angiogenic | open | 0.56 | 0.00 | 2026-04-10 | 0 | | neurovascular-biology |
| gap-pubmed-20260410- | What molecular mechanisms cause selective FOXF2 downregulation specifically afte | open | 0.64 | 0.00 | 2026-04-10 | 0 | | vascular-neurobiology |
| gap-pubmed-20260410- | Why does sTREM2 mediation vary substantially between P-tau (20-25%) and T-tau (3 | open | 0.75 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms link BIN1 polymorphisms to microglial sTREM2 release a | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do genetic and environmental factors interact to modify neuronal Ca2+ regula | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which disease proteins disrupt Ca2 | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does (+)-catechin cross the blood-nerve barrier to reach DRG Schwann cells a | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neuropathic-pain |
| gap-pubmed-20260410- | What determines the selectivity of (+)-catechin for the IL-34/CSF1R axis versus | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Which gene therapy approach will prove most safe and effective for clinical PKU | open | 0.57 | 0.00 | 2026-04-10 | 0 | | metabolic-neurodegeneration |
| gap-pubmed-20260410- | Why does dietary treatment for PKU remain inadequate despite decades of use and | open | 0.64 | 0.00 | 2026-04-10 | 0 | | metabolic-neurodegeneration |
| gap-pubmed-20260410- | What causes the abnormal cellular localization of ATXN2 in ALS spinal cord neuro | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do intermediate-length polyQ expansions (27-33 glutamines) in ATXN2 specific | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie the RNA-dependent TDP-43-ATXN2 interaction an | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What genetic risk mechanisms identified in African populations are missed in Eur | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do distinct linkage disequilibrium patterns in African populations affect Pa | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does tau dysfunction cause glucose homeostasis impairment or vice versa in AD pa | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms linking tau dysfunction to glucose ho | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Should tau-targeted therapies be redesigned to account for Aβ-tau synergy rather | open | 0.86 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why have anti-Aβ clinical trials failed despite the established role of Aβ in AD | partially_addressed | 0.88 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the specific molecular mechanisms underlying the synergistic interactio | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the selectivity of microglial pruning - why are some synapses ta | open | 0.81 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How does wogonin specifically activate the AKT/FoxO1 pathway to modulate microgl | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines the optimal timing and sequencing of biomarker implementation fo | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do blood-based biomarkers mechanistically reflect brain pathophysiology acro | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does wild-type huntingtin reduction produce equivalent therapeutic benefit a | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms explain sustained HD reversal persisting beyond huntingtin knock | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why is NETosis suppression specifically dependent on N-glycosylation rather than | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does AhR function as an E3 ligase and what determines its substrate specific | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How do therapeutic strategies targeting lysosomal biogenesis translate to functi | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What specific molecular mechanisms cause lysosomal dysfunction in microglia afte | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What determines Nur77's selective translocation from nucleus to mitochondria dur | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does memantine achieve post-translational modification of Nurr1 to promote s | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |